Drug intelligence / Profile preview

SRA-444

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

SRA-444 is an orally administered small molecule drug developed by Wyeth for the potential treatment of Alzheimer's disease. It acts as a serotonin 1A (5-HT1A) receptor antagonist. The drug was investigated in early clinical trials, including phase 1 studies to assess safety, tolerability, pharmacokinetics, and receptor occupancy in healthy elderly subjects and patients with Alzheimer's disease. As of the latest available information, development has not progressed beyond phase 1 and no further development has been reported[1][2][3][4].

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on SRA-444.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRA-444.

Explore the full profile